Key Points:
Preferred Medication
Medically reviewed by. Last updated on June 13, 2025.
Antipsychotic medications are a class of drugs that help to manage symptoms of schizophrenia and bipolar disorder. They work by affecting the balance of certain neurotransmitters in the brain, like serotonin and dopamine.
These medications are commonly prescribed to people who have conditions like schizophrenia, bipolar disorder, and depression.
Some people have difficulty taking certain antipsychotics and are prescribed them for other reasons, such as weight loss, or to treat other conditions.
Antipsychotics work by altering the levels of chemicals in the brain that influence mood and behavior.
They include:
Antipsychotics like olanzapine (Zyprexa) and quetiapine (Seroquel) can help to manage symptoms of schizophrenia by balancing the chemicals in the brain that can cause hallucinations and delusions.
But some antipsychotics, like olanzapine and ziprasidone (Geodon), also help to control mood and behaviors like anxiety and depression.
These medications are commonly prescribed for people who have conditions like bipolar disorder or schizophrenia.
Antipsychotics like olanzapine (Zyprexa) and quetiapine (Seroquel) help to balance chemicals in the brain that can affect mood, sleep, appetite, and body weight.
Antipsychotics are not a cure for schizophrenia, but they can help to manage symptoms like hallucinations and delusions.
But some antipsychotics, like olanzapine (Zyprexa), can help to treat symptoms such as aggression, impulsivity, and poor coordination.
Atypical antipsychotics like olanzapine (Zyprexa) and quetiapine (Seroquel) are usually used to manage symptoms of bipolar disorder or schizophrenia.
They can also help to control mood, anxiety, and other symptoms related to bipolar disorder or schizophrenia.
Atypical antipsychotics such as olanzapine (Zyprexa) and quetiapine (Seroquel) can be effective in managing hallucinations and delusions.
However, they can also reduce the frequency of hallucinations and delusions. They are sometimes used to treat agitation and behavior in people with ADHD, as well as in children.
The company said yesterday that the patent for the first-ever version of Olumiant, the world's most profitable diabetes drug, has been invalidated. The drug is a newer version of Eli Lilly's blockbuster drug for treating diabetes and was launched this year by the drugmaker Pfizer.
Pfizer is facing stiff competition from Eli Lilly and has already secured the first-ever version of the drug, a version of the company's cholesterol-lowering drug that has seen the latest version of the drug gain traction.
Pfizer announced yesterday that the patent for the first-ever version of Olumiant, the world's most profitable diabetes drug, has been invalidated. The drug was launched by Eli Lilly in March this year. Olumiant is expected to be available by mid-May.
Pfizer's latest patent application, filed on Oct. 14, is for a generic version of Zyprexa, the blockbuster drug that had been on the market since 2007. Eli Lilly has the patent, but Pfizer is trying to bring the product to market in the U. S. with an aggressive strategy to avoid generic competition.
The company says it will seek approval for a generic version of Olumiant, but it will have to demonstrate to the U. Food and Drug Administration that the drug is effective and safe.
Lilly, which launched the drug in April 2007, has been struggling to keep up with the onslaught of generic competition. In the past, its patent has expired, leaving many companies in the market.
While Pfizer, with the drugmaker's patent for Zyprexa to maintain, is waiting to see the company's first generic version of the drug, it's the first time that the drug has been rejected twice since 2002.
Pfizer has already secured an exclusive 180-day supply for the new version, which will be available through Dec. 6, according to company documents. The company's patent for the next-generation version, called XRX, is expected to expire in 2014. It will be marketed as a generic, rather than a branded version.
Meanwhile, Eli Lilly's patent on Zyprexa, which expires in 2010, has expired, and the patent for the drug's generic version, which is now a non-active drug, is now in its final stages.
Pfizer and Eli Lilly are also trying to bring the drug to market in the U. with a "strong strategy to avoid generic competition" and a "strong marketing plan to avoid generic competition" to ensure it can continue to make money on the drug. The company says it plans to take a larger step toward that goal this year.
Lilly and Eli Lilly are expected to face stiff competition from Eli Lilly, a drugmaker that has been struggling to keep up with the onslaught of generic competition. The company said yesterday that it will seek approval for a generic version of Zyprexa, but it will have to demonstrate to the FDA that the drug is effective and safe.Pfizer's patent for Zyprexa, which is expected to be available in the U. by May, was invalidated by a judge in October 2006 because of a technical problem in the patent for the drug. The patent on Zyprexa expired in October 2006, but it still maintains patent protection.
The company said yesterday that it would seek approval for a generic version of Zyprexa, but it will have to demonstrate to the FDA that the drug is effective and safe.
Lilly is also trying to bring the drug to market with a "strong marketing plan to avoid generic competition," which has been dubbed "the generic anti-obesity drug" by critics.
Lilly has been trying to bring the drug to market with an aggressive strategy to avoid generic competition. In the past, it has sought approval for a generic version of its cholesterol-lowering drug, a drug that has gained popularity since its introduction in the late 1990s. Its patent has expired in 2002 and is still pending approval.
The drugmaker has already secured a 180-day supply for the drug, a "strong marketing plan to avoid generic competition," according to a company documents.
In addition to Eli Lilly's recent acquisition of AstraZeneca, which filed for the drug in April 2006, the two companies have filed several patents, including a number of those that have been blocked by the Food and Drug Administration.
The new patent applications for a number of patents covering the drug have been filed in the U. S., with the first patent application for the drug pending in October 2007.
Olanzapine is an antipsychotic drug used to treat schizophrenia (now schizophrenia) in elderly patients with dementia-related psychosis. It works by blocking the release of dopamine and norepinephrine in the synapses of the brain. It can be taken as an antipsychotic (such as olanzapine). It can also be used in the treatment of depression.
Olanzapine is usually taken once daily at bedtime for the treatment of schizophrenia. For schizophrenia, the dosage of Olanzapine is 100 mg once a day. For olanzapine to treat dementia-related psychosis, it must be used for a minimum of 2 weeks before the onset of symptoms.
Olanzapine can increase your blood sugar, which can also lead to weight gain and metabolic changes. It should not be used in patients with diabetes mellitus (diabetes) or hyperglycemia (high blood sugar). Talk to your doctor before taking Olanzapine if you are receiving a blood test for glucose (Glucose Trizivirine, Glucose White Test, Glucose White Blood Pressure Test). This is because Olanzapine can lower blood sugar levels. If you have diabetes, check your diabetes medicine, diet, and exercise habits.
The most common side effects of Olanzapine include:
Please note:The information in this leaflet is for general information purposes only and does not constitute medical advice.
ReadRead the Patient Information Leaflet provided by your pharmacist before you start taking Olanzapine and each time you get a refill. If you have any questions, please feel free to contact your pharmacist or doctor.
NameOtherName of last RefillStoreDrug NameOlanzapineBrand NameGeneric NameDrug TypePharmaceutical FormForm / TabletDrug FormDrug / Capsule / Suspension
Pharmaceutical Form : Tablet Form : Tablet
Pharmaceutical Form / Tablet / Tablet / Tablet / Tablet / Tablet / Tablet / Tablet / Tablet / Tablet / Tablet / Tablet / Tablet / Oral Suspension : (mL / 1mL / 10mL / 20mL / 40mL)
Pharmaceutical Form / Tablet / Tablet / Tablet / Oral Suspension : (mL / 1 mL / 1 mL / 10 mL / 20 mL / 40 mL / 40 mL)
Olanzapine can also be used in the treatment of depression. It can also be used in the treatment of schizophrenia. Olanzapine can reduce the effects of serotonin syndrome in the brain, which is caused by elevated serotonin levels. It can also have a positive effect on cognitive function and attention in patients with dementia-related psychosis.
On November 28, the Food and Drug Administration (FDA) approved Zyprexa (olanzapine) as an extended-release, once-a-day treatment for schizophrenia. On November 25, the FDA approved Zyprexa (olanzapine) for the treatment of schizophrenia. On November 28, the FDA approved Zyprexa (olanzapine) as an extended-release treatment for the acute treatment of adult patients with the following: acute manic or mixed episodes associated with bipolar I disorder or mixed episodes associated with bipolar disorder, acute depressive episodes associated with bipolar I disorder, acute manic episodes associated with bipolar disorder, acute mixed episodes associated with bipolar disorder, acute relapses associated with bipolar I disorder, acute schizophrenia associated with bipolar disorder, acute mixed episodes associated with bipolar disorder, acute schizophrenia associated with bipolar disorder.
Zyprexa (olanzapine) is a drug that is prescribed for the treatment of schizophrenia, bipolar I disorder, and manic or mixed episodes associated with bipolar disorder. It works by blocking certain chemicals in the brain that are involved in the manic and depressive episodes. Olanzapine is also approved to treat schizophrenia. The exact mechanism of action of Zyprexa is not fully understood. The efficacy and safety of Zyprexa are based on the following: the long-term effect of the drug on various neurotransmitters in the brain and its long-term effect on mood and behavior. Olanzapine is aripiprazole.
The Food and Drug Administration (FDA) has approved Zyprexa (olanzapine) for the treatment of patients with schizophrenia. Zyprexa is a drug that is prescribed for the treatment of schizophrenia, bipolar I disorder, and manic or mixed episodes associated with bipolar disorder. Zyprexa is also approved to treat schizophrenia.
Stade de France Pharmacy